Abstract
Mucin-type O-glycans are upregulated and aberrantly glycosylated in many carcinomas. O-glycan Core 1 (Galβ1-3GalNAcα-O-), also called Thomsen-Friedenreich disaccharide, is a cryptic structure overexpressed in cancer cells through modification of its glycosyltransferase profile. This molecule is a useful model for study of carbohydrate immunogenicity as well as a candidate for active specific immunotherapy of cancer patients. Several strategies are discussed for enhancing immune response to a particular region of carbohydrate: carbohydrate-protein conjugation, linkers, synthetic clustered sugars, chemical modifications, peptide / protein mimetics, and molecular rotation.
Keywords: thomsen-friedenreich disaccharide, mucin-type o-glycans, o-glycan core 1, glycosyltransferase, immunogenicity, carbohydrate-protein conjugation,, synthetic clustered sugars, peptide/protein mimetics, molecular rotation
Current Cancer Drug Targets
Title: Thomsen-Friedenreich Disaccharide Immunogenicity
Volume: 3 Issue: 6
Author(s): Fernando J. Irazoqui and Gustavo A. Nores
Affiliation:
Keywords: thomsen-friedenreich disaccharide, mucin-type o-glycans, o-glycan core 1, glycosyltransferase, immunogenicity, carbohydrate-protein conjugation,, synthetic clustered sugars, peptide/protein mimetics, molecular rotation
Abstract: Mucin-type O-glycans are upregulated and aberrantly glycosylated in many carcinomas. O-glycan Core 1 (Galβ1-3GalNAcα-O-), also called Thomsen-Friedenreich disaccharide, is a cryptic structure overexpressed in cancer cells through modification of its glycosyltransferase profile. This molecule is a useful model for study of carbohydrate immunogenicity as well as a candidate for active specific immunotherapy of cancer patients. Several strategies are discussed for enhancing immune response to a particular region of carbohydrate: carbohydrate-protein conjugation, linkers, synthetic clustered sugars, chemical modifications, peptide / protein mimetics, and molecular rotation.
Export Options
About this article
Cite this article as:
Irazoqui J. Fernando and Nores A. Gustavo, Thomsen-Friedenreich Disaccharide Immunogenicity, Current Cancer Drug Targets 2003; 3 (6) . https://dx.doi.org/10.2174/1568009033481714
DOI https://dx.doi.org/10.2174/1568009033481714 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Review on Melatonin’s Effects in Cancer: Potential Mechanisms
Anti-Cancer Agents in Medicinal Chemistry Overview of Current Immunotherapies Targeting Mutated KRAS Cancers
Current Topics in Medicinal Chemistry Targeting the Multifaceted HuR Protein, Benefits and Caveats
Current Drug Targets Recent Advances in Optical Cancer Imaging of EGF Receptors
Current Medicinal Chemistry Developing Phytoestrogens for Breast Cancer Prevention
Anti-Cancer Agents in Medicinal Chemistry Structural and Bioactive Properties of 3-O-Methylfunicone
Mini-Reviews in Medicinal Chemistry Recent Development in Targeting PI3K-Akt-mTOR Signaling for Anticancer Therapeutic Strategies
Anti-Cancer Agents in Medicinal Chemistry Fluorescence-Functionalized Magnetic Nanocomposites as Tracking and Targeting Systems: Their Preparation and Characterizations
Current Nanoscience Lipoprotein(a): Medical Treatment Options for an Elusive Molecule
Current Pharmaceutical Design Biomaterial Scaffolds for Mesenchymal Stem Cell Based Therapy Aimed at Tissue Engineering Application for Osteoarthritis
Recent Patents on Nanomedicine Engineered Nanoparticles for Improved Vasoactive Intestinal Peptide (VIP) Biomedical Applications
Recent Patents on Nanomedicine Urotensin-II Receptor: A Double Identity Receptor Involved in Vasoconstriction and in the Development of Digestive Tract Cancers and other Tumors
Current Cancer Drug Targets Challenges from Clustering Analysis to Knowledge Discovery in Molecular Biomechanics
Current Bioinformatics Testosterone Deficiency Syndrome: Cellular and Molecular Mechanism of Action
Current Aging Science Polymeric Nano-Assemblies as Emerging Delivery Carriers for Therapeutic Applications: A Review of Recent Patents
Recent Patents on Nanotechnology Triterpenoids for Cancer Prevention and Treatment: Current Status and Future Prospects
Current Pharmaceutical Biotechnology Editorial (Metastases Prevention is the Cure)
Current Cancer Therapy Reviews The Antibiotic Potential of Prokaryotic IMP Dehydrogenase Inhibitors
Current Medicinal Chemistry A Comprehensive Review on Recent Developments in the Field of Biological Applications of Potent Pyrazolines Derived from Chalcone Precursors
Letters in Drug Design & Discovery Role of Natural Killer Cell Activity in the Pathogenesis of Endometriosis
Current Medicinal Chemistry